67 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
substantial harm. There can be no assurance that we will resolve any adverse event related to any of our products to the satisfaction of the FDA or any … be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities that our product candidates are safe and effective
S-8
EX-5.1
CRBU
Caribou Biosciences Inc
11 Mar 24
Registration of securities for employees
5:08pm
of originals or copies certified or otherwise identified to our satisfaction as being true reproductions of originals, of all such documents, records
8-K
EX-99.2
ggu7ou3tp0b20g4
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
8-K
p7jj 6nl12xyn5
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
8-K
EX-5.1
rqca1jb16exc8 ta
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
8-K
EX-99.1
yf2ahf8vjzk 7u4g3ep
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
424B5
4js35knw
14 Jul 23
Prospectus supplement for primary offering
5:31pm
424B5
m8f69l2h
13 Jul 23
Prospectus supplement for primary offering
4:56pm
8-K
EX-10.1
sre69i08eymhn6qwv
6 Jul 23
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
8:01am
ARS
pynx jvni12k
28 Apr 23
Annual report to shareholders
12:00am